ArticlePhysics and imaging in radiation oncology2022
Magnetic resonance imaging-guided radiotherapy for intermediate- and high-risk prostate cancer: Trade-off between planning target volume margin and online plan adaption.
Article in Physics and imaging in radiation oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- From CBCT to MR-Linac in Image-Guided Prostate Cancer Radiotherapy Towards Treatment Personalization.Current oncology (Toronto, Ont.) · 2025Review
- Reconstructed dose and geometric coverage for tight margins using intrafraction re-planning on an integrated magnetic resonance imaging and linear accelerator system for prostate cancer patients.Physics and imaging in radiation oncology · 2025Article
- Target coverage and organs at risk dose in hypofractionated salvage radiotherapy after prostatectomy.Physics and imaging in radiation oncology · 2024Article
- Treatment planning evaluation and experimental validation of the magnetic resonance-based intrafraction drift correction.Physics and imaging in radiation oncology · 2024Article
- Intra-fractional geometric and dose/volume metric variations of magnetic resonance imaging-guided stereotactic radiotherapy of prostate bed after radical prostatectomy.Physics and imaging in radiation oncology · 2024Article
- [The MIRAGE Trial (MRI-guided stereotactic body radiotherapy for prostate cancer) - Precision at its best?]Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Article
- Impact of technological advances in treatment planning, image guidance, and treatment delivery on target margin design for prostate cancer radiotherapy: an updated review.The British journal of radiology · 2024Review
- Predicting cervical cancer target motion using a multivariate regression model to enable patient selection for adaptive external beam radiotherapy.Physics and imaging in radiation oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Magnetic resonance-guided radiotherapy with daily plan adaptation for intermediate- and high-risk prostate cancer is time and labor intensive. Fifty adapted plans with 3 mm planning target volume (PTV)-margin were compared with non-adapted plans using 3 or 5 mm margins. Adequate (V95% ≥ 95%) prostate coverage was achieved in 49 fractions with 5 mm PTV without plan adaptation, however, coverage of the seminal vesicles (SV) was insufficient in 15 of 50 fractions. There was no insufficient coverage for prostate and SV using plan adaptation with 3 mm. Hence, daily adaptation is recommended to obtain adequate SV-coverage when using 3 mm PTV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.